Plasma concentration range of sotoracib

Sotorasib is a targeted drug specifically targeted at the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC). Understanding the range of their plasma concentrations is critical to optimizing treatment efficacy and monitoring patient safety.

In clinical trials, the pharmacokinetic characteristics of sotoraxib showed changes in its concentration in the body. Sotorasiib is highly bioavailable orally, with peak concentrations typically reaching peak concentrations within 3 to 6 hours after dosing. Based on available clinical data, steady-state plasma concentrations of sotoraxib are typically achieved at an initial dose of 960 mg, with a concentration range of 2000-8000 ng/mL (i.e., 2-8 µg/mL). This range varies depending on factors such as individual differences, absorption, and time of administration.

The patient's age, gender, weight, liver and kidney function and other physiological characteristics will affect the absorption and metabolism of the drug, resulting in differences in blood drug concentration. Certain drugs may affect the metabolism of sotoraxib, resulting in increased or decreased plasma concentrations. In particular, those drugs that affect CYP3A4 enzymes, such as CYP3A4 inhibitors and inducers, will significantly affect the plasma concentration of sotoraxib. Sotorasiib is better absorbed when taken on an empty stomach. Food intake may affect drug bioavailability, resulting in changes in blood drug concentrations.

Monitoring sotoraxib plasma concentrations is critical for assessing treatment efficacy and adjusting treatment regimens. In actual clinical practice, although there are currently no guidelines for routine monitoring of blood drug concentrations, monitoring of blood drug concentrations may be necessary for some special patients (such as patients with hepatic and renal insufficiency or patients receiving other treatments that affect drug metabolism).

By monitoring blood drug concentrations, doctors can better evaluate the effectiveness and safety of treatment, and adjust the dosage or change the treatment plan when necessary to achieve the best therapeutic effect and reduce the occurrence of adverse reactions. In general, understanding the blood concentration range of sotoraxib and its influencing factors can help doctors develop more personalized treatment plans to ensure patients get the best treatment results.